The HCPLive Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...
November 30th 2023
November 25th 2023
Advancing Cardiology Care Through Professional Education®: The 6th Annual New York Cardio-Endo-Renal Collaborative (NY CERC)
Transfusion-Related Iron Overload–Evidence-Based Approaches to Improve Chelation Outcomes
Community Practice Connections™: Expert Perspectives on the Evolving Treatment Paradigm in Heart Failure Management
Amplifying the Role of Accurate Diagnosis and New Therapeutic Options in the Treatment of Hemolytic Anemias
Medical Crossfire®: Updates in Continuous Glucose Monitoring—Having the Important Conversations With Your Patients
Evaluating the Recent Advancements in Chronic Kidney Disease Treatment: A Case-Based Approach to Managing CKD and Related Comorbidities
Elevating Care for PAH: Applying Recommended Management Approaches to Maximize Outcomes
In our September 2023 cardiology month in review, the editorial team of HCPLive Cardiology highlights a trio of regulatory decision from the FDA and a group of 5 different articles spotlighting data from phase 2 or phase 3 trials.
A study of more than 500 patients with severe psoriasis provides further insight into the association between severe psoriasis and cardiovascular disease risk, demonstrating coronary microvascular dysfunction was present in 30% of this cohort.
Anthos Therapeutics halts their phase 2 AZALEA-TIMI 71 trial due to significant reduction in bleeding events with abelacimab, making it a potential breakthrough in anticoagulation therapy for atrial fibrillation.
Elliot Elias, MD, MPH, provides perspective on recent advances in structural heart disease as well as highlighting the upcoming 40th annual Echocardiography and Structural Heart Symposium at Baptist Health.
Data from the EMPEROR-Reduced trial provide insight into the effects of empagliflozin in patients with heart failure with reduced ejection fraction based on baseline diuretic use from the phase 3 trial.
At ERS International Congress 2023, new data related to use of sotatercept offered providers additional insight into the effects of the agent in people with PAH.